Stocktoria
SELLAS Life Sciences Group, Inc. SLS
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2008-03-12
SELLAS Life Sciences Group, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $1.0M | $7.6M | $1.9M | $0 | — | — | — |
| R&D expense | — | — | — | — | $15.7M | $9.3M | $7.3M | $8.8M | $6.1M | $11.4M |
| SG&A expense | $12.3M | $12.4M | $13.9M | $12.6M | $11.3M | $9.6M | $9.9M | $12.8M | $15.1M | $4.6M |
| Operating income | -$28.3M | -$31.5M | -$37.9M | -$42.0M | -$25.3M | -$17.0M | -$20.0M | — | -$23.0M | -$16.0M |
| Income tax | $0 | $0 | $0 | $0 | -$237,000 | -$17,000 | -$81,000 | -$1.4M | $253,000 | $1,000 |
| Net income | -$26.9M | -$30.9M | -$37.3M | -$41.3M | -$20.7M | -$16.8M | -$19.3M | -$27.7M | -$23.8M | -$17.7M |
| EPS (diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | — | — | — | — |
| Operating cash flow | -$28.4M | -$35.4M | -$31.4M | -$23.8M | -$26.0M | -$10.4M | -$17.6M | -$30.4M | -$11.0M | -$33.2M |
| Free cash flow | — | — | — | — | — | — | — | — | — | -$33.2M |
| Cash & equivalents | $71.8M | $13.9M | $2.5M | $17.1M | $21.4M | $35.3M | $7.3M | $5.3M | $2.3M | $6.0M |
| Total assets | $78.3M | $19.4M | $6.2M | $20.9M | $26.3M | $46.0M | $16.6M | $16.9M | $33.5M | $6.4M |
| Total liabilities | $7.5M | $10.0M | $14.2M | $16.1M | $5.9M | $18.1M | $10.5M | $11.7M | $31.5M | $11.4M |
| Shareholders' equity | $70.9M | $9.5M | -$8.0M | $4.9M | $20.3M | $28.0M | $6.1M | $5.2M | $2.1M | -$5.0M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | -100.0% | -86.8% | +300.0% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.